# Genmab Reports $4.24 Billion in Q3 2026 DARZALEX Sales

- URL: https://stocks.freetheai.org/news/genmab-reports-4-24-billion-in-q3-2026-darzalex-sales-8c6b3d
- Published: 2026-10-13T10:22:00Z
- Category: earnings; sentiment: bullish; impact: high
- Symbols: [NASDAQ:GMAB](https://stocks.freetheai.org/symbols/NASDAQ-GMAB), [OMXCOP:GMAB](https://stocks.freetheai.org/symbols/OMXCOP-GMAB)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Genmab A/S (NASDAQ:GMAB) announced that worldwide net trade sales for its antibody therapy DARZALEX reached USD 4,239 million in the third quarter of 2026. The sales figures, reported by commercialization partner Johnson & Johnson, include both intravenous and subcutaneous formulations sold in the U.S. as DARZALEX FASPRO.

Sales in the United States generated USD 2,528 million during the quarter, while rest of world markets contributed USD 1,711 million. Under an exclusive global license agreement, Genmab collects royalties on all worldwide sales of the therapy.

Investors will continue tracking DARZALEX commercial performance and adoption across regional markets to gauge ongoing royalty revenue growth.

## Key points

- Worldwide Q3 2026 net trade sales for DARZALEX reached USD 4,239 million.
- U.S. sales accounted for USD 2,528 million, while rest of world sales were USD 1,711 million.
- Genmab earns royalties on global sales under an exclusive licensing deal with Johnson & Johnson.

## Questions and answers

### What were global sales of DARZALEX in the third quarter of 2026?

Worldwide net trade sales of DARZALEX reached USD 4,239 million in Q3 2026, comprising USD 2,528 million in the U.S. and USD 1,711 million in the rest of the world.

### How does Genmab earn revenue from DARZALEX?

Genmab receives royalties on worldwide net sales of DARZALEX from Johnson & Johnson, which holds an exclusive license to manufacture and commercialize the treatment.